-
GUT: Anti-SARS-CoV-2 antibody response weakened in patients with IBD treated with infliximab
Time of Update: 2021-03-30
Nicholas A Kennedy sought to determine whether IBD patients treated with infliximab had attenuated the serological response to SARS-CoV-2 infection.
The serological response to SARS-CoV-2 infection in patients receiving infliximab treatment decreased, and the seroprevalence rate, seroconversion rate, and antibody reactivity decreased.
-
Nat Commun: Iron-regulated microtubule cytoskeleton protein can be a potential target for the treatment of iron-restricted anemia
Time of Update: 2021-03-30
The results of this study found the cytoskeleton components in the iron restriction response of red blood cells and confirmed its potential for targeted therapy in ACDI.
-
Blood Advances: Elderly patients with follicular lymphoma should not be disqualified for treatment because of their age
Time of Update: 2021-03-30
The early disease outcomes of FL patients over 70 years old and younger patients who participated in the clinical trial treatment were similar.
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.
-
JAMA: The effect of increasing the dose of preventive anticoagulant therapy on the prognosis of ICU patients with new coronary pneumonia
Time of Update: 2021-03-30
7%) had the primary endpoint event, while the standard dose prevention group was 126 (44.
7%) in the enoxaparin medium-dose group had the primary endpoint event, while the standard-dose prevention group was 126 cases (44.
-
JCEM: The relationship between TSH and thyroid hormones and lymphopenia in patients with bacterial sepsis and COVID-19
Time of Update: 2021-03-30
It can be seen that in patients with severe infections such as bacterial sepsis and COVID-19, abnormal thyroid function is associated with lymphopenia, but future research needs to determine whether there is a causal relationship .
1210/clinem/dgab148" target="_blank" rel="noopener">The association of TSH and thyroid hormones with lymphopenia in bacterial sepsis and COVID-19 .
-
Innovent's PI3Kδ inhibitor parsaclisib plans to be included in breakthrough treatment products
Time of Update: 2021-03-30
This clinical data highlights the potential of Parsaclisib as a treatment option for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
-
Blocking interleukin-22 can reduce stress-induced anemia in mice | "Nature-Immunology" paper
Time of Update: 2021-03-27
Laurie Glimcher and colleagues at the Dana-Farber Cancer Institute in Boston, Massachusetts, USA, and colleagues identified a stress-induced feature that can lead to a decrease in red blood cells in mice with abnormal expression of Riok2-the human Riok2 gene is derived from chromosome 5.
-
2021 EBMT | ASCT sequential allo-HSCT followed by maintenance treatment can improve the efficacy of MM patients?
Time of Update: 2021-03-27
Nicolaus Kröger and others in Germany conducted a study comparing autologous hematopoietic stem cell transplantation (ASCT) sequential allo-HSCT (auto-allo TSCT) followed by maintenance therapy, and ASCT sequential ASCT (auto-auto TSCT) followed In order to maintain the efficacy of treatment in newly diagnosed MM patients, the results of the study will be announced at the 47th European Association of Blood and Bone Marrow Transplantation (EBMT 2021) in 2021.
-
An article to understand the pathological and epidemiological characteristics of DLBCL
Time of Update: 2021-03-27
These cases are now classified as "high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements", are commonly referred to as double or triple-hit lymphomas, and are associated with poor prognosis for R-CHOP treatment.
-
Understand NEJM in 2 minutes: pegcetacoplan treats paroxysmal nocturnal hemoglobinuria
Time of Update: 2021-03-27
[Editor's note] NEJM Quick Take introduces an article of the latest NEJM in 2 minutes in the form of animation. "NEJM Frontiers of Medicine" updates the video summary of the current NEJM treatises e
-
When "Vernal Equinox" Meets "Platelet Day" | Professor Fang Jianpei Talks about Children's ITP Management
Time of Update: 2021-03-27
Although childhood ITP is a benign self-limiting disease, 80% of cases can return to normal platelet counts within 12 months after diagnosis, but there are still about 20% of children whose disease course lasts for more than 1 year.
-
2021 EBMT | TBF program can improve disease-free survival of AML patients in complete remission
Time of Update: 2021-03-27
2020), cytepa + busulfan + fludarabine (TBF) The pretreatment program can reduce the risk of recurrence in patients with acute myeloid leukemia (AML) in the first and second remission (CR1/CR2) stages.
-
2021 EBMT | Allo-HCT followed by bortezomib in the treatment of MM can significantly reduce the incidence of moderate/severe cGVHD
Time of Update: 2021-03-27
hypothesized that the use of bortezomib (BTZ) maintenance therapy after allo-HCT could reduce the recurrence rate and the incidence of cGVHD in high-risk, young MM patients, and conducted clinical studies to try to determine the effect of bone marrow measurable residual disease (MRD) The impact of future disease progression.
-
2021 EBMT｜Axi-cel speaks with real-world data and treats R/R LBCL ORR up to 78%
Time of Update: 2021-03-27
The cytokine release syndrome (CRS) and immune effector cell-related neurotoxic syndrome (ICANS) were graded according to the ASTCT consensus standard, and the remission was assessed according to the Lugano standard.
The median time from approval to infusion was 54 days.
The median time from leukocyte separation to infusion was 39 days.
-
One step closer to listing! Innovative T cell immunotherapy releases clinical data analysis丨Yi Mai Meng broke the news
Time of Update: 2021-03-27
Recommended reading: Atara's unique immune cell therapy enters Phase III clinical trials, and is expected to become the first "off-the-shelf" T cell product approved for marketing Yimaihei Technology tab-cel® is currently under Atara's research and development progress The fastest T cell immunotherapy; in addition to EBV+PTLD patients after transplantation who failed rituximab treatment, it is also planned to be used for other EBV-related hematomas and solid tumors including nasopharyngeal carcinoma.
-
Innovent's PI3Kδ inhibitor parsaclisib plans to be included in breakthrough treatment products
Time of Update: 2021-03-26
This clinical data highlights the potential of Parsaclisib as a treatment option for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
-
Nat Commun: Iron-regulated microtubule cytoskeleton protein can be a potential target for the treatment of iron-restricted anemia
Time of Update: 2021-03-26
The results of this study found the cytoskeleton components in the iron restriction response of red blood cells and confirmed its potential for targeted therapy in ACDI.
-
JAMA: The effect of increasing the dose of preventive anticoagulant therapy on the prognosis of ICU patients with new coronary pneumonia
Time of Update: 2021-03-26
7%) had the primary endpoint event, while the standard dose prevention group was 126 (44.
7%) in the enoxaparin medium-dose group had the primary endpoint event, while the standard-dose prevention group was 126 cases (44.
-
Blood Advances: Elderly patients with follicular lymphoma should not be disqualified for treatment because of their age
Time of Update: 2021-03-26
The early disease outcomes of FL patients over 70 years old and younger patients who participated in the clinical trial treatment were similar.
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.
-
GUT: Anti-SARS-CoV-2 antibody response weakened in patients with IBD treated with infliximab
Time of Update: 2021-03-26
Nicholas A Kennedy sought to determine whether IBD patients treated with infliximab had attenuated the serological response to SARS-CoV-2 infection.
The serological response to SARS-CoV-2 infection in patients receiving infliximab treatment decreased, and the seroprevalence rate, seroconversion rate, and antibody reactivity decreased.
